Related Experiment Videos

Plasma adiponectin, T94G gene polymorphism and PAI-1 in patients with and without hypertension

Jing-Ren Jeng1

  • 1Division of Cardiology, Department of Internal Medicine, and Neuro-Medical Scientific Center, Buddhist Tzu-Chi General Hospital, Tzu-Chi University, Hualien, Taiwan, Republic of China.

Cardiology
|June 3, 2006
PubMed

Insights

The adiponectin T94G gene polymorphism is linked to lower adiponectin and higher plasminogen activator inhibitor-1 (PAI-1) levels in Chinese individuals. This genetic link may influence adiponectin and PAI-1 regulation, particularly in men and normotensive subjects.

Area of Science:

  • Genetics
  • Endocrinology
  • Cardiovascular Disease

Background:

  • Reduced adiponectin is linked to metabolic syndrome, type 2 diabetes, and coronary artery disease.
  • The relationship between the adiponectin T94G genotype, plasma adiponectin, and plasminogen activator inhibitor-1 (PAI-1) is not well understood.

Purpose of the Study:

  • To investigate the associations between the adiponectin T94G genotype, plasma adiponectin levels, PAI-1 levels, and blood pressure in a Chinese population.

Main Methods:

  • Genotyping for the adiponectin T94G polymorphism was performed on 568 Chinese patients.
  • Plasma levels of adiponectin and PAI-1 were measured.
  • Patients were categorized into hypertensive and normotensive groups.

Main Results:

  • Hypertensive patients had lower adiponectin and higher PAI-1 levels compared to normotensive subjects.
  • Plasma adiponectin levels were inversely correlated with PAI-1 activity and antigen.
  • The TT genotype group exhibited significantly lower plasma adiponectin and higher plasma PAI-1 activity and antigen compared to the GG genotype group.

Conclusions:

  • The adiponectin T94G TT genotype is associated with lower plasma adiponectin and higher plasma PAI-1 levels in the Chinese population.
  • This genotype's effect on adiponectin and PAI-1 appears more pronounced in men and normotensive individuals.
  • The adiponectin gene T94G polymorphism may play a role in regulating circulating adiponectin and PAI-1 levels.
Abstract

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Peripheral Artery Disease I: Introduction01:30

Peripheral Artery Disease I: Introduction

Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...
Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Hypertension and Regulation of Blood Pressure01:18

Hypertension and Regulation of Blood Pressure

Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...